Clinical Trials Logo

Acute Disease clinical trials

View clinical trials related to Acute Disease.

Filter by:

NCT ID: NCT00097734 Recruiting - Acute Disease Clinical Trials

Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis

Start date: July 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy (by assessing the clinical success of treatment) of intravenous antibiotic therapy with ertapenem in patients with acute attacks of sigmoid diverticulitis for 4 vs. 7 days.

NCT ID: NCT00093158 Completed - Clinical trials for Myocardial Infarction

Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)

Start date: August 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention [PCI]; Arm A): 1. Bivalirudin with routine GPIIb/IIIa inhibition (either started upfront or at the time of PCI; Arm B) provides non-inferior or superior overall clinical outcomes and 2. Bivalirudin alone (Arm C) reduces clinically significant bleeding. An important secondary objective for this comparison is to show that bivalirudin is not inferior for ischemic complications.

NCT ID: NCT00073372 Terminated - Clinical trials for Cerebrovascular Accident

A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)

Start date: October 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effectiveness of abciximab in the treatment of acute ischemic stroke.

NCT ID: NCT00048958 Active, not recruiting - Multiple Myeloma Clinical Trials

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

Start date: June 1984
Phase:
Study type: Observational

Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.

NCT ID: NCT00042718 Completed - Chronic Bronchitis Clinical Trials

A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.

Start date: November 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of four oral antibiotic treatment regimens for bacterial infections in patients with chronic bronchitis. The study goals are to demonstrate that 1) levofloxacin 750 mg once daily for three days is no worse than azithromycin 250 mg twice a day for one day and then 250 mg once a day for four more days, and 2) levofloxacin 750 mg once daily for five days is no worse than amoxicillin/ clavulanate (875/125 mg) twice daily for 10 days.